Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 13,629 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Cancer
Interventions: polymorphism analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Not listed
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Postoperative Pain, Acute, Skin Cancer
Interventions: Meloxicam 7.5 mg, Meloxicam 15 mg, Acetaminophen 500mg; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 110 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Precancerous Condition
Interventions: perillyl alcohol, placebo; Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Metastatic Breast Cancer
Interventions: Sorafenib, Ixabepilone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 15
States / cities: Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more

Conditions: Metastatic Melanoma
Interventions: Bevacizumab, Everolimus; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more

Conditions: Lymphedema
Interventions: Intermittent, gradient, pneumatic compression device; Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 21 Years to 95 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Multiple Sclerosis
Interventions: No Treatment Arm, Topical Preparation H arm; Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: S6G5T-3, S6G5T-8; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 9 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Actinic Keratosis
Interventions: LEO 43204 gel, Vehicle gel; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Dermatomyositis
Interventions: Octagam 10%, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Huntington Beach, California • Los Angeles, California • Orange, California + 14 more

Conditions: Breast Neoplasms
Interventions: Fine needle aspiration biopsy (FNAB), Sentinel Lymph Node Biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions: CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions: Standard of Care, BIOxHEAL (human amniotic membrane allograft); Other · Biological
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boardman, Ohio

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide; Drug
Lead sponsor: Shire; Industry
Eligibility: 16 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 40
States / cities: Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more

Conditions: Psoriasis
Interventions: risankizumab; Drug
Lead sponsor: Oregon Medical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Netherton Syndrome
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Rancho Santa Margarita, California • Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Androgenetic Alopecia
Interventions: LH80 PRO, Sham Device; Device
Lead sponsor: Theradome, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Newnan, Georgia • Portland, Oregon + 1 more

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
Interventions: SB 11285, Atezolizumab; Drug
Lead sponsor: invoX Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Breast Neoplasms
Interventions: MEDI4736; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions: Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more

Conditions: AIDS, HIV Infections
Interventions: recombinant human growth hormone, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Fulvestrant, Tamoxifen; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: New York, New York

Conditions: Discoid Lupus Erythematosus (DLE)
Interventions: etanercept(Enbrel®); Drug
Lead sponsor: Florida Academic Dermatology Centers; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Genital Herpes Simplex Type 2
Interventions: Observational; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more

Search by objective public record fields.

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Meloxicam in Mohs Micrographic Surgery

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

RAD001 Plus Bevacizumab in Metastatic Melanoma

Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

High Dose Risankizumab for Psoriasis

Natural History of Netherton Syndrome

Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Physiologic Growth Hormone Effects in HIV Lipodystrophy

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity